Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 91 to 100 of 1090 total matches.
Fenoldopam--A New Drug for Parenteral Treatment of Severe Hypertension
The Medical Letter on Drugs and Therapeutics • May 22, 1998 (Issue 1027)
cautiously in patients with glaucoma (DE Evirett et al, J Clin Pharmacol, 37:312, 1997).
DRUG INTERACTIONS ...
Fenoldopam mesylte (Corlopam - Neurex), a peripheral dopamine-1 (DA1) agonist, has been approved by the FDA for parenteral use in lowering blood pressure. The manufacturer claims that, unlike other parenteral antihypertensive agents, fenoldopam not only lowers blood pressure but also maintains or improves renal function.
Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
depressant effects, including
somnolence/sedation, dizziness, and confusion.
Drug Interactions: Use ...
The FDA has approved the oral GABAA receptor
modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression
(PPD). Zuranolone is the second drug to be approved
for this indication; brexanolone (Zulresso), another
GABAA receptor modulator, was approved for IV
treatment of PPD in 2019.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):201-3 doi:10.58347/tml.2023.1692a | Show Introduction Hide Introduction
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • Dec 14, 2020 (Issue 1613)
, vomiting, nervousness, headache, and insomnia, and it interacts with many other drugs. At high serum ...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations
of asthma in the emergency department is not
discussed here.
Comparison Table: Drugs for Parkinson's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
SOME ADVERSE EFFECTS
DRUG and FOOD INTERACTIONS
Most effective treatment for the motor symptoms ...
View the Comparison Table: Drugs for Parkinson's Disease
Atorvastatin - A New Lipid-lowering Drug
The Medical Letter on Drugs and Therapeutics • Mar 28, 1997 (Issue 997)
. As
with other statins, high doses of atorvastatin can induce malignant tumors in rats and mice.
DRUG INTERACTIONS ...
Atorvastatin (Lipitor - Parke-Davis), an HMG-CoA reductase inhibitor (or 'statin'), was recently approved by the US Food and Drug Administration for treatment of primary hypercholesterolemia and mixed dyslipidemia. A single stereoisomer of a pyrrole derivative, the new drug is chemically different from other statins.
New Drugs for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Nov 12, 2012 (Issue 1403)
or activated charcoal for 11 days).
Drug Interactions – Teriflunomide inhibits CYP2C8
and may increase ...
In recent years, several new drugs have been
approved by the FDA for use in multiple sclerosis
(MS), and many others are in the pipeline. Most
recently, teriflunomide (Aubagio – Genzyme) became
the second oral drug to be approved by the FDA for
treatment of relapsing forms of MS.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
of Antihyperglycemic Drugs .......................p 180
Some Drug Interactions with Antihyperglycemic Drugs ........p ...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.
Drugs for MRSA with Reduced Susceptibility to Vancomycin
The Medical Letter on Drugs and Therapeutics • May 04, 2009 (Issue 1311)
thrombophlebitis and has
substantial potential for adverse drug interactions, and
tigecycline (Tygacil), which ...
The recent Medical Letter article on vancomycin dosing and monitoring briefly mentioned use of an alternative antibiotic for treatment of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Some readers have asked for more information on this subject.
Click here to view the free full article.
Click here to view the free full article.
A 4-Drug Combination (Viekira Pak) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • Feb 02, 2015 (Issue 1461)
female partners are pregnant.
DRUG INTERACTIONS — Unlike ledipasvir or sofosbuvir,
which are not CYP ...
The FDA has approved Viekira Pak (Abbvie), a fixed-dose
combination of two new direct-acting antiviral
agents (ombitasvir, paritaprevir) with the pharmacologic
enhancer ritonavir in one tablet, co-packaged with
a third new direct-acting antiviral agent (dasabuvir) in
a second tablet, for oral treatment of chronic hepatitis
C virus (HCV) genotype 1 infection. Genotype 1 is
responsible for 70-80% of HCV infections in the US.
Drugs for Intermittent Claudication
The Medical Letter on Drugs and Therapeutics • Feb 16, 2004 (Issue 1176)
Drugs for Intermittent Claudication ...
Management of intermittent claudication, the most common symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic treatment (WR Hiatt, N Engl J Med 2001; 344:1608; RM Schainfeld, J Am Board Fam Pract 2001; 14:443).